The 2015 edition of the revised MTC management guideline (5) states that FNAC, ultrasound, plasma calcitonin concentration, carcinoembryonic antigen values, and RET gene mutation status can be used as assists in the diagnosis of MTC. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.